Tech Company Financing Transactions
SpliceBio Funding Round
On 6/11/2025, SpliceBio landed $135 million in Series B funding from EQT Life Sciences, Sanofi Ventures and Asabys Partners.
Transaction Overview
Company Name
Announced On
6/11/2025
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance the clinical development of its lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and the observational POLARIS study.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Parc Científic de Barcelona, Baldiri Reixac, 10
Barcelona, 08028
Spain
Barcelona, 08028
Spain
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
SpliceBio is a genetic medicines company harnessing its proprietary Protein Splicing platform to develop the next generation of gene therapies. Our platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Miquel Vila-Perelló
Browse more venture capital transactions:
Prev: 6/11/2025: Antares Therapeutics venture capital transaction
Next: 6/12/2025: Zorro venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs